SAXS for Biopharmaceuticals & Biosimilars
Small‑angle X‑ray scattering for biosimilar comparability studies and biologic structural characterization — higher-order structure analysis in native solution without crystallization.
SAXS for Biologics Characterization
SAXS (and NMR) are the only laboratory methods capable of probing proteins, peptides and biopolymers in native solution environments — making them uniquely suited to study biologics in conditions that closely mimic their natural biological state.
Most of the useful information identified by SAXS is related to:
- Higher‑order structure of biologics in solution
- Oligomeric state and molecular mass determination
- Aggregation pathways and stability assessment
- Conformational space of flexible systems
An advantage of this method is that it permits the observation of objects that have not been stained or fixed, showing them in their native aqueous environment — in contrast to X‑ray crystallography, which generally requires placing samples in non‑physiological environments.
Reconstruction of Higher‑Order Structure
The atomic structure of biopolymers in a crystalline state is traditionally determined using monocrystal X‑ray diffraction. While this is a powerful and well‑established approach, a drawback is the necessity of a crystallization step. This can be a very challenging task for some pharmaceutically‑important substances, such as membrane proteins.
The structural properties of a biopolymer in a natural biological environment, such as its higher‑order structure, may be investigated using SAXS and often becomes the subject of independent interest. The reason for this is related to the fact that the actual structure of a biopolymer in solution may differ from its crystalline structure due to its conformational flexibility and tendency to form oligomers or aggregates.
SAXS is recognized as the tool of choice for determining the tertiary and quaternary structure of a biopolymer in a close‑to‑natural aqueous environment. Alongside solution NMR and cryo‑microscopy, SAXS is one of the only available methods for visualizing the actual higher‑order structure of a biopolymer in its native environment.
The ab‑initio or model‑based reconstruction of a low‑resolution envelope structure using SAXS may be possible with as little as a 0.25 wt% formulation of the biopolymer in the appropriate buffer.
Example: Immunoglobulin IgG1
Envelope structure reconstructed from solution scattering experiments at 0.25% wt in buffer, validated against high‑resolution crystallographic structure from the Protein Data Bank.
Low Concentration Requirements
Structural determination possible with minimal sample quantities in native buffer conditions.
Native Environment
Observation in physiological conditions without crystallization, staining, or fixation artifacts.
Investigation of Peptides & Flexible Systems
For peptides with a defined 3D structure in dispersion, the methods of ab‑initio reconstruction may be useful for accessing dimensions, oligomeric states and approximate molecular masses.
Together with the envelope structure, useful structural invariants such as radius of gyration (Rg) and excluded volume are also determined.
Peptide Characterization
Example: HIV fusion inhibitor — trimeric structure reconstruction validated against high‑resolution crystallographic data (1AIK entry in PDB).
Flexible & Unfolded Proteins
For naturally unfolded proteins, ensemble modeling approaches (following Bernadó et al., 2007) present the system as a collection of the most probable conformations matching experimental data.
Conformational Analysis
Example: α‑synuclein conformers in the presence of SDS — identification of "U‑shape" cluster suspected as precursor to neurotoxicity.
SAXS for Stability Studies
Biological pharmaceutical products are known to be particularly sensitive to environmental factors such as temperature change, oxidation, light and shear. Periodic monitoring of the physico‑chemical properties of an intermediate or finished drug substance is required to prove it meets shelf‑life specifications.
Information about the structural parameters obtained from SAXS measurements, such as envelope shape and invariants (mass and radius of gyration), serve as important markers that are correlated with biological activity.
If changes are identified over time, it is an indication of the potential degradation of the biological drug product.
Structural Monitoring
Track changes in Rg, molecular mass, and envelope shape over time and under stress conditions.
Aggregation Detection
Early detection of aggregation and conformational changes that may affect biological activity.
Environmental Stress Testing
Assessment of sensitivity to temperature, pH, oxidation, and mechanical stress.
DANNALAB SAXS Capabilities for Biologics
Structural Characterization
- Ab‑initio envelope reconstruction
- Oligomerization state determination
- Molecular mass estimation
- Analysis possible with 0.25 wt% concentration
Industrial cGMP SAXS
- Rarely available under cGMP in industry
- 21 CFR Part 11 compliant data
- QA‑approved deliverables
- Fast turnaround, committed timelines
Flexible Systems
Ensemble modeling for disordered proteins
Method Development
Fit‑for‑purpose SAXS methods
Temperature Control
In‑situ 4°C to 90°C studies
Native Conditions
No crystallization required
Applications
Monoclonal Antibodies
Structural characterization, aggregation monitoring, and stability assessment of therapeutic antibodies.
Biosimilars Development
Structural comparison between biosimilar candidates and reference products.
Protein Therapeutics
Higher‑order structure determination for enzymes, hormones, and growth factors.
Peptide Drugs
Oligomerization and structural analysis of therapeutic peptides in formulation.
Fusion Proteins
Domain orientation and flexibility analysis for engineered fusion constructs.
Membrane Proteins
Structural studies of membrane proteins in detergent micelles or nanodiscs.
Out-of-Patent Biologics
Structural characterization supporting reformulation and novel delivery approaches for biologics with expired patent protection.
Biosimilar Structural Comparability
SAXS provides solution-state structural evidence essential for demonstrating biosimilarity — a key component of the "totality of evidence" required by FDA and EMA for biosimilar approval.
As major biologics lose patent protection, SAXS comparability studies help establish structural equivalence between biosimilar candidates and reference products.
Reference Product Comparison
Side-by-side SAXS analysis of biosimilar candidates against originator products, demonstrating higher-order structural similarity in native solution conditions.
Higher-Order Structure (HOS)
Envelope shape, radius of gyration (Rg), and molecular dimensions as structural fingerprints for biosimilar characterization.
Analytical Similarity
Quantitative comparison of SAXS-derived parameters supporting the analytical similarity assessment required for 351(k) approval.
Interchangeability Support
Enhanced structural characterization for interchangeable biologics requiring demonstration of consistent structure across switching studies.
Key Biosimilar Categories
Monoclonal Antibodies
Adalimumab, trastuzumab, rituximab biosimilars
Fusion Proteins
Etanercept and similar Fc-fusion constructs
Hormones & Growth Factors
Insulin, EPO, G-CSF biosimilars
Therapeutic Enzymes
Replacement enzymes for rare diseases
LNP-Based Biologic Delivery
Lipid nanoparticles offer solutions for challenging biologic delivery — protecting proteins and peptides from degradation while enabling targeted delivery and sustained release.
Protein Encapsulation
SAXS characterization of therapeutic proteins formulated within lipid nanoparticles for enhanced stability and targeted delivery.
Peptide Delivery Systems
Structural analysis of LNP-encapsulated peptides, including GLP-1 agonists and insulin formulations for novel delivery routes.
Antibody-LNP Conjugates
Characterization of lipid nanoparticles functionalized with antibodies or antibody fragments for active targeting.
Oral Biologic Delivery
Emerging LNP platforms for oral delivery of biologics — structural characterization supporting formulation development.
Regulatory Pathway Support
DANNALAB provides SAXS characterization data suitable for multiple biopharmaceutical regulatory pathways, with cGMP-compliant documentation for global submissions.
351(k) Biosimilar Applications
Structural comparability data demonstrating biosimilarity to FDA-licensed reference products, supporting the analytical similarity tier of assessment.
BLA Support
Higher-order structure characterization for Biologics License Applications, including lot release and stability-indicating specifications.
EMA Biosimilar Dossiers
SAXS data meeting European regulatory expectations for biosimilar quality comparability exercises.
Comparability Protocols
Post-approval change support with structural comparison between pre- and post-change products for manufacturing site transfers or process changes.
All data delivered with cGMP documentation, 21 CFR Part 11 compliance, and QA-approved certificates suitable for direct inclusion in regulatory submissions.
Specialized Biopharmaceutical Services
Biosimilar HOS Testing
Higher-order structure comparability analysis for biosimilar regulatory submissions. Demonstrate structural similarity to reference products.
mRNA-LNP Characterization
Lipid nanoparticle structural analysis for mRNA vaccines and therapeutics. Bilayer organization, encapsulation, particle architecture.
Protein Aggregation Testing
Early detection of aggregation and conformational changes in biologics. Stability assessment and formulation screening.
Related Services
SAXS Method Information
Detailed technical information about our SAXS methods and capabilities.
Drug Delivery Systems
SAXS characterization of liposomes, LNPs, and other nanoparticulate delivery systems.
cGMP Compliance
Full details on our quality system, certifications, and regulatory compliance.
Discuss Your Biologics Project
Contact our technical team to discuss your biopharmaceutical characterization needs, request a quote, or get expert advice on SAXS method development.